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ABSTRACT
Objective: The study aimed to have a prospective study of serum folate concentration and hemoglobin (Hb%) in cervical carcinoma patients.
Methods: The study was conducted on women suffering from carcinoma cervix. The research was conducted in the Gynecological Outpatient 
Department (OPD) of the Oncology Unit in Mahavir Cancer Sansthan Patna, Bihar. The study period was from May 2016 to April 2017. The sample was 
collected after face to face interview by Figo staging and the sample was taken regularly. As a result strong association of Hb% and carcinoma cervix 
was found with the mean value of lower than 11.12, which is lower than the normal range of Hb%. As per the further estimation of folic acid, the level 
of cervical cancer is low.
Results: The data were estimated with help of tools such as SPSS 16.0 and PRISMA 5.0. The Hb% the mean value of patients was estimated to be 
lower than 11.12, which is not under the normal range of Hb%, that is, nearly 12.5 mg/dl. The low mean value shows less Hb% content which leads 
to anemia in normal beings as well as in patients with cervical cancer. A strong association of Hb% which affected to patients in carcinoma cervix can 
be seen in the graph that the mean value of patients low 11.12±0.20 which not comes under normal range of Hb%, that is, 12.5 mg/dl. The R square 
value is 0.9556.
Conclusion: As per our study, we have estimated that the folic acid level in cervical cancer is low. The -normal range of folic acid level in plasma serum 
is 2.2–20 ug/ml. The mean of 20 control cases, new cervical cancer patients, on treating patients, and follow-up patients is 11.08, 2.206, 3.554, and 
2.783, respectively. The control 11.08 shows the better level in plasma serum level comes under a normal range of folic acid level.
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INTRODUCTION
As per the current scenario, one of the most wide-ranging gynae cancers 
among women is cervical which causes significant deaths in women 
around the world. It mostly occurs in the low economy or developing 
countries. Many types of cervical cancers expand from irregular cells at 
the aperture of the cervix and it is known as squamous cell carcinoma. 
The further development is from gland cells, but that is not common. 
Those tumors are called adenocarcinomas. It has been stated that there 
are approximately 12,000 women tested positive for cervical cancer 
per year. The diagnosis can be done in three types which are cervical 
cytology (Papanicolaou or “Pap” test), Pap/human papillomavirus 
(HPV) co-test, and HPV-only test [1]. There are almost one in five 
women diagnosed with cervical cancer in India and the country has the 
greatest load of such patients [2,3].
Another most reliable method of treatment of metastatic cervical cancer 
for years is platinum-based chemotherapy but has not shown any major 
improvements in survival rate [4,5]. The other causes of carcinoma 
cervix are etiological points various oncogenic microorganisms, 
dietary factors, low socio income group, immune system, and 
epigenetic factors [6,7]. This leads to understandable implications for 
primary avoidance, that is, vaccination and later secondary prevention, 
that is, screening. In most of the developing countries, screening and 
diagnosis are aimed at early classification of high-risk HPV lesions 
during HPV testing and Pap smears [8]. The most convincing reason 
for deaths is the loss of resource availability and it is thus considered a 
serious social health issue [9,10].
As per the studies and patient perspective, cervical cancer is a sexually 
transmitted disease, thus it can be prevented. A study based on ethnic 
minority women in the United Kingdom specified some barriers 
against the diagnosis including low awareness, fright, awkwardness, 
and disgrace, and low professed risk [3,11]. At present, there are new 
compounds that are in trials with hopeful results and simultaneously 
there are also numerous new strategies that might cover the unmet 
need in cervical cancer [4].
As per the WHO and some studies, it has been already estimated that if the 
range of the hemoglobin (Hb%) is approximate>12 g/dL for anemia in 
non-pregnant females over 15 years, it further significantly deteriorate 
acute mucocutaneous toxicity in patients with highly developed cervical 
cancer in patients with patients getting chemoradiation [12,13].
As per the knowledge gathered, there are not many studies which are 
indicating an investigation of the folate status of any specific region of 
the country/state. Thus, we have conducted this kind of study in the 
Bihar region on women suffering from carcinoma cervix. Thus, the 
purpose of this prospective study was to identify nutritional factors 
(folic acid) deficiency associated with immunosuppressant of cervical 
cancers among patients.
METHODS
It is a prospective longitudinal cohort study with local patients 
(Northern region) followed over time. The investigation was 
quantitative, and the research design was mostly case–control. The 
study approach was mostly analytical and was employed to review the 
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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risk of folate production in cervical cancer patients. The research was 
conducted in the Gynecological Outpatient Department (OPD) of the 
Oncology Unit in Mahavir Cancer Sansthan Patna, Bihar. The consent 
was taken individually from every participant. Before the initiation 
of the study, the ethical approval was taken from the institute (MCS/
Admin/2016-17/1055/12).
The study period was from May 2016 to April 2017. The group was 
formed of similar patients (cohorts) who differ in respect to certain 
factors such as age at marriage, addiction, dietary habits (veg/non-
veg), frequency of meal, and dairy products. The study was planned 
based on analytical analysis employed to assess factors that affect the 
outcome of the result. The patient who was taken into the inclusion 
criteria (Groups I–IV) was suffering from cervical cancer. The patients 
which were tested negative in the diagnosis of cervical cancer were 
dropped into the control group. As per the literature, the sample size 
of the group required to conduct parametric tests was reported to be 
at a minimum of 60.
The study is been designed based on the previous study of Tiwari and 
Gupta (2008) is a simple and sensitive method designed to develop 
the estimation of ascorbic acid by ultraviolet (UV) spectrophotometry. 
In this method, Systronics UV-visible spectroscopy instrument is 
used for spectral estimation. Ascorbic acid is treated with potassium 
iodate-iodide solution under acidic conditions to liberate iodine. The 
Rhodamine – B dye was measured at 555 nm. The concentration of 
1.2–12 µg ascorbic acid obeys the beer’s law. Statistically, the method 
was accurate and precise [14].
All cases were qualified for the study if they met the criteria like that 
comes under inclusion criteria.
Inclusion criteria
The following criteria were included in the study:
•	 All diagnosed and confirmed patients of cervix cancer
•	 Age between 18 and 80 years
•	 Women willing to participate in the research study.
Exclusion criteria
The following criteria were excluded from the study:
•	 Women which are diagnosed with cervical dysplasia
•	 Defaulter patients (the patients who already counseled in another 
study)
•	 Patients who were diagnosed with other major disorders such as 
AIDs and HIV.
The sampling for cases was performed employing the detailing 
technique. All members of the study population taken as participants 
were made to fill the detail sheet about them and along with that, 
the diagnosis was properly studied. All participants available in the 
gynecology OPD during the data collection period were included in the 
study as per the fixed criteria.
Sample size
The total samples taken for the study were 200 patients which were 
divided into four groups. The study was conducted with a sum of 200 
patients, with 180 cases and 20 controls. Apart from control, all the 
other groups had 60 patients each. Group I was the control which had 
healthy individuals. In Group II, individuals were new patients with 
cervix cancer before initiation of treatment, Group III had individuals 
which came during treatment, and Group IV had individuals who 
came during follow-up routine checkups after treatment. The follow-
up patients were those who already completed their therapy and 
treatment and come to routine check-in 3 months.
Tool for data collection
Face-to-face interviews were conducted with participants. The 
diagnosis and the patient blood history helped us to collect the 
estimated value of the Hb% of the patient. The questioner sheet was 
prepared as per the literature which was filled by each individual 
and the interview has consisted of a series of questions for collating 
information about a particular topic from patients individually. 
Questions were asked in Hindi and included identification detail 
(Name, contact, and address), any history of cancer in the family if 
yes give detail, marital status, religion, addiction, and dietary habits. 
There were questions about some fixed parameters such as menstrual 
history, body mass index, weight, blood group, and comorbidity. Any 
information related to the symptoms of carcinoma cervix was also 
noted. Finally, the social (Cause of coming in advance stage, who 
brought you to the hospital, etc.) and practical (diagnosis) assessment 
were also taken into consideration.
Sample collection
For sample collection, the patients were marked from mild-to-severe 
as per the scale of Figo staging, and samples were taken at the regular 
interval. The Hb% rate was determined as per the standard laboratory 
procedure. The data were analyzed with the line graph. The rate 
of the hemoglobin varied as per the stage and the severity of the 
patient. Hemoglobin content decreased according to the cancer stage 
advancement.
Hb% estimation
A strong association of Hb% affected patients in carcinoma cervix 
(Fig. 1).
The Hb% the mean value of patients was estimated to be lower than 
11.12 which is not under the normal range of Hb%, that is, nearly 12.5 
mg/dl. The low mean value shows less Hb% content which leads to 
anemia in normal beings as well as in patients of cervical cancer.
Data analysis
Later for the estimation of the value of Hb%, the curve was created 
to estimate the probability of disease with the help of the statistical 
analysis. Data were statically analyzed by SPSS 16.0 to determine 
correlation between folate acid formation and the occurrence of cervix 
cancer. If the probability value is <0.05 so the data will be considered 
as statistically significant. Further suspected risk factors were analyzed 
for their outcome and determine the precaution and awareness for the 
protection of cervix cancer.
Preparation of calibration curve
Reagent preparation
We prepared ascorbic acid (Lobachemie): There Stock sol. of 
1000 g/ml was prepared by taking potassium iodate (0.2/mol) 
and dissolving it in 100 ml distilled water. After that, add potassium 
iodide (0.1/mol) dissolved in 100 ml distilled water. Furthermore, add 
hydrochloric acid (0.02 mol/l) dissolved in 90 ml distilled water and 
stir it properly and make it up to 100 ml.
For rhodamin blue (0.05% aq solution): Dissolve it in distilled water 
and make it up to 100 ml. For sodium acetate (2.0 mol/l): Dissolve it in 
10 ml distilled water.
Fig. 1: Association of Hb% which affected to patients in carcinoma 
cervix
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A stock solution of ascorbic acid
100 mg of ascorbic acid was weighed and transferred into a 25 ml 
volumetric flask. Solubilized properly dissolve in distilled water. 
The volume was made up to 100 ml with respective to get the final 
solubilization.
Absorption maxima determination using UV/VIS spectrophotometer
From the stock solution of 1000 µg/ml, 1 ml aliquots were withdrawn 
and separately diluted with distilled water. In a calibrated volumetric 
flask, the solution 100 µg/ml was scanned in the range of 555 nm to 
determine using UV/visible spectrophotometer. Later in the results, it 
was found to be beyond Beer’s range. Therefore, 1 ml was aliquoted 
from the 100 µg/ml solution of stock solution was taken and diluted to 
10 ml, hence getting the concentration of 10 µg/ml. This solution was 
again scanned and absorption maxima was determined.
10–50 µl of ascorbic acid transferred to 25 ml graduated tube separately. 
0.4 ml mixture of potassium iodide and potassium iodate pipette 1 ml 
of 0.2 mole/l HCL were added. Then, the mixture was gently shaken, 
then yellow color was appeared (yellow color appearance indicates 
liberation of iodine). Then, 1 ml of 0.5% Rhodamine blue solution was 
added to solution mixture followed by addition of 2 ml of 0.2 mol/l 
sodium acetate and then solution mixture and was shaken for 2 min. 
The content was diluted up to 25 ml with distilled water and the 
mixture was kept for 10–15 min. Then absorbance was measured on 
UV at 555 nm.
Preparation of calibration curve (Figs. 2 and 3)
Reagent preparation
For ascorbic acid (Lobachemie) add stock sol. of 1000 g/ml was 
prepared by dissolving 10 mg of ascorbic acid in 100 ml of water. For 
potassium iodate (0.2/mol) 4.25 g was dissolved in 100 ml distilled 
water.
Potassium iodide (0.1/mol) was made by adding 1.660 g potassium 
iodide in 100 ml distilled water. Hydrochloric acid (0.02 mol/l) was 
made by adding 17 µl concentrated HCL in 90 ml distilled water and 
stir it properly and make it up to 100 ml by adding extra distilled water.
Rhodamin blue (0.05% aq solution) was made by adding 0.05 g of 
rhodamin blue and was dissolved in distilled water and made it up to 
100 ml.
Preparation of calibration curve of Folic acid in distilled water
The calibration curve of folic acid was prepared in distilled water at 555 
nm using a UV spectrophotometer. Beer’s range [Ind. Council Chem., 
Vol. 25, No. 2, 2008] was found between 10 and 50 µg/ml and R² was 
0.955 the curve.
Estimation of folic acid
Later folate acid estimation was done by collecting the fresh blood 
sample of the patients, from the pathology department through 
intravenous. The folic acid assessment was done in almost 200 patients 
who were prepared to give blood samples to a pathologist. For this 
study, there were four groups (detail above in the sample size) of the 
patient in which controls were tested to recognize the normal value 
of folic acid, and it was set as the standard. The difference in the folic 
acid level of groups and control was later observed by the data analysis. 
The groups were divided as per for evaluating that condition between 
the new patient, on treating patients and follow-up patients. Controls 
clarified standard folic acid level and new patients gave an evaluation 
of lately diagnosed level that did not take concurrent chemoradiation 
therapy. For stable treatment patients, the folic acid and multi-vitamins 
dose were suggested that can alter the level.
Folic acid estimation
A strong association of Hb% which affected to patients in carcinoma 
cervix can be seen in the graph that the mean value of patients low 
11.12±0.20 which not comes under the normal range of Hb%, that is, 
12.5 mg/dl. The R square value is 0.9556.
As per our study, we have estimated that the folic acid level in cervical 
cancer is low. The -normal range of folic acid level in plasma serum 
is 2.2–20 ug/ml. The mean of 20 control cases, new cervical cancer 
patients, on treating patients, and follow-up patients is 11.08, 2.206, 
3.554, and 2.783, respectively. The control 11.08 shows the better 
level in plasma serum level comes under the normal range of folic acid 
level. However, the new patients of cervical cancer patients are low 
and in on-treatment patients are slightly high then new patients and 
majorly low then control due to folic acid therapy and multivitamin 
during concurrent and radiation treatment for boosting the immunity 
and Hb% of patients, generally during chemotherapy and concurrent 
radiation therapy the folic acid level lowered. After completion of 
treatment the folic acid level below as usual due to poor diet habit, as 
results of follow-up patients shows. This result shows that consistently 
low folic acid level in plasma serum in cervical cancer patients in 
comparison to the normal folic acid level in plasma serum. We observe 
the folic acid deficiency in cervix cancer patients which is associated 
with low Hb% in blood and that follows anemic condition in these 
patients. These patients have asked some questionnaire related to 
dietary habit, we observe that these patients have low or poor diets 
in their daily routine. By table Hb% and basal metabolic rate of cervix 
cancer patients are also low which is also directly related to folic acid 
level.
Fig. 2: Calibration curve of folic acid
Fig. 3: Calibration curve of folic acid (prism software)
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DISCUSSION
The major role played by folate is in DNA synthesis and methylation, 
which leads to DNA reliability in maintenance and also helps in gene 
expression [15]. The folates have the capability of modulating DNA by 
the process of methylation, repair, and combination which suggests its 
role in tumorigenesis. It has been proven in studies that risk factors for 
cervical intraepithelial neoplasia (CIN) and cervical cancer comprise 
socioeconomic status, smoking, younger age at first intercourse, race, 
elevated parity, and use of oral contraceptive [15-18]. In addition to that, 
growing evidence has concerned nutrients, mainly folate, in the process 
of cervical carcinogenesis using DNA methylation and fusion [19,20]. 
Some studies [14,21-25], but not all [26], have recommended that folate 
intake/supplement, as well as levels of folate, plays a crucial role in 
cervical carcinogenesis.
Folate deficiency has been projected as one of the causative factors in the 
development of cervical and another type of cancer such as breast, lung, 
and brain, pancreatic, and colorectal cancers [22]. According to a study, 
low levels of serum folate might increase the hazard of CIN progression. 
Besides, potential synergy could exist among low serum folate levels 
and high-risk HPV infection to encourage CIN expansion [23]. Some 
other epidemiologic studies have also established the relationship 
between folate serum and CIN almost all the subjects were small-scale 
outpatient from different living statuses based on dietary habits and 
lifestyles [24].
Zhang and contemporaries in their research estimated that elevated 
homocysteine levels and folate insufficiency, as regulated by serum 
folate level, can be associated with amplified overall risk of cancer in 
83 case–control studies meta-analysis. Hence, it has been clarified that 
higher or at least sufficient levels have also proven to be protective for 
cervical cancer. Augmented risk of cervical cancer resulted in deficiency 
per serum folate in an Asian population, but a similar result was not 
seen in American cases. Serum levels used to classify deficiency were 
diverse between several populations, and some were superior to what 
is reported in the text [25].
Yang et al. in their study estimated that that serum folate is inversely 
connected with the threat of higher-grade CIN in Chinese women 
moreover with or without high-risk HPV contamination. Therefore, 
preservation of normal serum folate levels might establish important 
for dropping the risk of CIN in patients [26]. The novel approach known 
as folate receptor-mediated staining solution detection has been 
planned as effectual testing for CIN and other ovarian cancer. It has 
been proven higher specificity than HPV and TCT testing [27,28].
The role of folate in cervical carcinogenesis is still uncertain, but facts 
from epidemiologic data are moderate and are indicating a protective 
outcome of folate [29,30]. A cross-sectional study performed in the 
United States established that higher circulating folate in the post 
building up era was connected with a low risk of CIN in the body. 
Several case–control studies resulted that lack of micronutrients, like 
folate, had a notably augmented risk of formation of cervical lesions and 
later, in contrast, other data of case–control and cohort study did not 
find any connection [31,32].
As per the study of Yang et al., a cross-sectional investigation in 2304 
women aged 19–65 years was done. The study indicated that that 
serum folate is inversely linked with the threat of higher-grade CIN in 
the Chinese population either with or with no high-risk HPV contagion. 
This concluded that the maintenance of normal serum folate levels 
may prove important for reducing the risk of CIN in women [27]. In 
countries like South-West Nigeria, the study showed that low serum 
folate is not separately associated with the augmented risk of invasive 
cervical cancer [33].
Limitation of the study
In addition, the influential effects of specific nutrients on cervical cancer 
can be done individually. However, this study also has a limitation. 
We only showed the relationships between folate in cervical cancer 
progression, it indicates that folate may play an essential role in cervical 
lesions through impacting on DNA methylation and which suppresses 
the immunity level of the body, low immunity allows HPV and which 
is main risk factors of cervical cancer which shows by the result in our 
study.
CONCLUSION
The fundamental mechanism of folate in the pathogenesis of cervical 
cancer is not elucidated to date. Folate is involved in the transfer 
and metabolic development of carbon in the body and is implicated 
in DNA methylation, playing an important role in the stabilization of 
the DNA arrangement and the appearance of genes. Low folate levels 
in the body influence the DNA methylation procedure in cells, which 
help the DNA chain to fracture and growing chromosome vulnerability. 
This concludes that if the normal transcription and appearance of DNA 
are affected; then the risk of cancer cells increases and the growth and 
prognosis of CIN are inclined.
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